Prevent-Plus, a progressive leader in the management and prevention of surgical site infections, highlights Preventogen’s key scientific and clinical contributions in 2024-2025 that are shaping the future of advanced polymers for infection prevention
Prevent-Plus presented two oral abstracts at the 2025 Surgical Infection Society Annual Meeting on May 13th:
- A review of a prospective database of patients undergoing elective surgery at a tertiary academic hospital with 76 documented cases showing a zero (0%) rate of Surgical Site Infection (SSI) compared to an expected SSI risk of 4.13%
- An IRB approved retrospective review of a prospective database of patients that had de novo Hemodialysis Catheter placements for Hemodialysis at three dialysis centers, showing zero (0%) exit site infections and zero (0%) catheter-related bloodstream infections (CRBSIs) in 38 patients over more than 4,100 catheter days vs. a historical baseline of 5.2% catheters removed secondary to infection
St. Louis, MO (May 14, 2024) Prevent-Plus, a leader in infection prevention technologies, announced the presentation of new clinical data sets (abstracts) highlighting its proprietary product, Preventogen, a novel microbicidal elastomeric liquid polymer designed to reduce surgical site infections (SSIs). The data was shared at the 44th Annual Meeting of the Surgical Infection Society, held May 13th in Philadelphia.
SURGICAL PATIENTS
Surgical site infections are among the most common complications following surgery and can lead to increased morbidity, hospital readmissions, and healthcare costs. Preventogen is formulated to create a protective microbicidal barrier at the incision site, offering an additional layer of defense during the critical postoperative healing period.
The abstract, titled “The Impact of a Novel Microbicidal Elastomeric Liquid Polymer (Preventogen) on Surgical Site Infections in Patients Undergoing Surgery” (Abstract MO15), was presented by medical student Hachem Bey of the Baylor College of Medicine. The study evaluated 76 surgical cases with an expected SSI risk of 4.13%. The case mix included 51% clean and 49% clean-contaminated surgeries.
At the 30-day follow-up, no surgical site infections were reported in any of the patients, a result suggesting strong potential for Preventogen in reducing the risk of SSIs across a variety of surgical procedures.
Dr. Samir Awad, MD, MPH, Professor of Surgery, Vice Chair Surgical Quality & Safety at the Baylor College of Medicine commented on the findings during the meeting, stating: “Preventogen has demonstrated significant promise as a preventative tool in surgical settings. These results support its clinical value in helping reduce the burden of SSIs, which continues to be a major concern for hospitals and patients alike.”
DIALYSIS CATHETER PATIENTS
Catheter Related Bloodstream Infections (CRBSI) from the use of tunneled hemodialysis catheters (THDC) are reported to be 1.1 to 6.1 episodes per 1000 catheter days and are associated with increased morbidity, hospitalization and death.
The abstract, titled “Preliminary Results Using a Novel Microbicidal Liquid Polymer (Preventogen) for the Reduction of Catheter Site Infections in Patients Receiving Hemodialysis Through Tunneled Hemodialysis Catheters” (Abstract MO23), was presented by Dr. Samir Awad, MD, MPH, Professor of Surgery, Vice Chair Surgical Quality & Safety at the Baylor College of Medicine. To date, 38 of the 60 patients have been enrolled in this prospective study, with interim results over 4090 catheter days resulting in zero exit site infections and zero CRBSI vs. a historical infection rate of 4.1 per 1000 catheter days (exit site infection) and 4.5 per 1000 catheter days (CRBSI).
Brad Chartrand, CEO of Prevent-Plus, stated, “The breadth and consistency of the data presented at the Surgical Infection Society Meeting reinforces the transformative potential of Preventogen across multiple market segments, demonstrating the capacity to significantly improve patient care around the world. Across the Preventogen clinical program, these results hold promise in addressing two major global health threats: Surgical Site Infections and Antimicrobial Resistance.”
About Prevent-Plus and Preventogen:
Prevent-Plus manufactures and markets a Class I FDA-cleared liquid polymer that provides both a microbicidal and physical barrier, making it well-suited for all individuals at risk of infection. Preventogen is Prevent-Plus’s hospital-grade product designed for use in clinical settings. This advanced wound care solution provides a non-antibiotic approach to infection prevention and optimal healing, killing microbes (bacteria, fungi, and viruses) on contact before forming a flexible, breathable polymer barrier. Preventogen has been clinically proven for a variety of both surgical and non-surgical wounds, significantly improving patient outcomes and quality of life.
